ArticleInternal medicine (Tokyo, Japan)2026
Investigation of Appropriate Telemedicine for Patients with Inflammatory Bowel Disease.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study explored the conditions for applying telemedicine to patients with inflammatory bowel disease (IBD), attempting to demonstrate that the application of telemedicine to patients with IBD does not adversely affect their condition and clarifying the form of telemedicine that meets the needs of patients with IBD. Methods Study 1 retrospectively investigated the application of telemedicine and its impact on IBD treatment, whereas Study 2 investigated the perceptions of telemedicine in patients with IBD. Patients Study 1 was conducted using the medical records of 267 patients with IBD who had been treated at our department throughout the financial years (FY) 2019 and 2020. In Study 2, a questionnaire survey was presented to 113 patients from Study 1, who agreed to complete the questionnaire. Results No patient background factors significantly influenced telemedicine implementation in FY 2020. A shorter disease duration, relapse in the previous FY, and lower Hb levels were significantly related to relapse in FY 2020, whereas the use of telemedicine was not related to relapse. The survey revealed that most patients with IBD preferred a conventional face-to-face treatment system; however, patients who had difficulty finding the time to visit the hospital tended to prefer telemedicine. Conclusion Telemedicine can be implemented in patients with IBD without adverse effects on their medical conditions; however, the appropriate conditions for applying telemedicine need to be clarified in the future. It is necessary to establish an IBD treatment system that satisfies patients' needs, considering the characteristics of those who wish to receive telemedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.